Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18988990 | ULTRA-HIGH-CELL-DENSITY MULTICELLULAR TISSUE LIFTING BIOPRINTING DEVICE ASSISTED BY OBLIQUE INCIDENT BULK WAVE AND PRINTING METHOD THEREFOR | December 2024 | April 2025 | Allow | 4 | 0 | 0 | No | No |
| 18822374 | APPLICATION OF NANO LAYERED DOUBLE HYDROXIDE IN CARTILAGE REGENERATION AND PREPARATION THEREOF | September 2024 | April 2025 | Allow | 8 | 1 | 1 | No | No |
| 18817528 | CD34 STEM CELL MIMICS | August 2024 | June 2025 | Allow | 10 | 1 | 1 | No | No |
| 18431132 | Egg Preparation in an Intelligent Automated In Vitro Fertilization and Intracytoplasmic Sperm Injection Platform | February 2024 | February 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18567880 | ISOLATED CELL MEMBRANE POTENTIAL DETECTION SYSTEM AND METHOD BASED ON MULTI-SPECTRAL MULTI-PARAMETER PHOTOSTIMULATION | December 2023 | November 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18351345 | METHOD FOR FORMING A POROUS CELL SUBSTRATE | July 2023 | October 2024 | Allow | 15 | 2 | 1 | Yes | No |
| 18199013 | NANOBARCODE FOR CONTROLLING CELL ADHESION AND DIFFERENTIATION OF STEM CELLS, PREPARATION METHOD THEREOF, AND METHOD OF CONTROLLING ADHESION AND DIFFERENTIATION OF STEM CELLS BY USING THE SAME | May 2023 | February 2025 | Allow | 21 | 1 | 0 | Yes | No |
| 18108699 | FIBROUS BIRTH TISSUE COMPOSITION AND METHOD OF USE | February 2023 | April 2025 | Allow | 26 | 1 | 1 | No | No |
| 17974395 | METHOD AND COMPOSITION FOR HYPOTHERMIC STORAGE OF PLACENTAL TISSUE | October 2022 | August 2024 | Allow | 22 | 1 | 0 | No | No |
| 17967250 | METHODS OF PREPARING PERSONALIZED BLOOD VESSELS | October 2022 | April 2025 | Allow | 30 | 1 | 1 | No | No |
| 17957579 | Control of Copolymer Compositions | September 2022 | March 2025 | Abandon | 29 | 1 | 1 | No | No |
| 17885167 | USE OF RAMAN SPECTROSCOPY TO MONITOR CULTURE MEDIUM | August 2022 | March 2025 | Allow | 31 | 1 | 0 | No | No |
| 17871149 | BIOLOGICALLY FUNCTIONAL SOFT TISSUE SCAFFOLDS AND IMPLANTS | July 2022 | April 2025 | Allow | 33 | 2 | 0 | No | No |
| 17700458 | USE OF STEM CELLS EXPRESSING MESENCHYMAL AND NEURONAL MARKERS AND COMPOSITIONS THEREOF TO TREAT NEUROLOGICAL DISEASE | March 2022 | September 2024 | Allow | 30 | 2 | 0 | Yes | No |
| 17577519 | SOFT TISSUE PROTEIN COMPOSITIONS, METHODS OF MAKING, AND USES THEREOF | January 2022 | September 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17566226 | Spray-Dried Blood Products and Methods of Making Same | December 2021 | February 2025 | Allow | 37 | 2 | 1 | Yes | No |
| 17612391 | APPARATUS AND METHODS FOR MEDICAL APPLICATIONS OF LASER DRIVEN MICROFLUID PUMPS | November 2021 | July 2025 | Allow | 43 | 1 | 1 | No | No |
| 17612187 | CELL SCAFFOLD COMPRISING AN ELECTRONIC CIRCUIT | November 2021 | June 2025 | Allow | 43 | 1 | 1 | No | No |
| 17503872 | USE OF CIRCULATING TUMOR CELL MITOTIC INDEX IN CANCER STRATIFICATION AND DIAGNOSTICS | October 2021 | June 2025 | Allow | 44 | 3 | 0 | No | No |
| 17500408 | AMNIOTIC FLUID CELL-DERIVED EXTRACELLULAR MATRIX AND USES THEREOF | October 2021 | August 2024 | Allow | 34 | 2 | 1 | No | No |
| 17463930 | HIGH EFFICIENCY MICROFLUIDIC PURIFICATION OF STEM CELLS TO IMPROVE TRANSPLANTS | September 2021 | December 2024 | Abandon | 40 | 3 | 0 | No | No |
| 17407349 | PRODUCTION OF RED BLOOD CELLS AND PLATELETS FROM STEM CELLS | August 2021 | May 2024 | Allow | 33 | 2 | 0 | No | No |
| 17424198 | ACOUSTIC CONCENTRATION, TRANSFER AND ANALYSIS OF SAMPLES CONTAINING PARTICLES | July 2021 | April 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17335726 | APPARATUS, SYSTEMS, AND METHODS FOR QUANTIFYING INFECTIOUS AGENTS | June 2021 | March 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17297805 | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS | May 2021 | June 2025 | Allow | 48 | 1 | 1 | No | No |
| 17308169 | METHOD AND DEVICE FOR UNIFORMLY TREATING ADHERENT CELLS | May 2021 | May 2025 | Allow | 49 | 1 | 0 | No | No |
| 17291591 | SYSTEMS FOR CELL CONTROL | May 2021 | February 2025 | Allow | 46 | 1 | 0 | Yes | No |
| 17246376 | NANOBARCODE FOR CONTROLLING CELL ADHESION AND DIFFERENTIATION OF STEM CELLS | April 2021 | September 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17235777 | METHODS FOR PROMOTING PROLIFERATION AND PROPAGATION OF STEM CELLS | April 2021 | September 2024 | Allow | 41 | 1 | 1 | No | No |
| 17206471 | Biological Fluid Filtration System | March 2021 | March 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17275991 | POLIOVIRUS RECEPTOR (PVR/CD155) KNOCKOUT CELLS DERIVED FROM RD (HUMAN RHABDOMYOSARCOMA) CELL LINE BY CRISPR | March 2021 | May 2025 | Allow | 50 | 1 | 1 | Yes | No |
| 17200351 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | March 2021 | May 2025 | Allow | 50 | 1 | 1 | No | No |
| 17256910 | MSC Prediction Algorithm | December 2020 | January 2025 | Allow | 49 | 1 | 1 | No | No |
| 17253067 | Method in Bioprocess Purification System | December 2020 | June 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 17252674 | MITOCHONDRIAL AUGMENTATION THERAPY WITH STEM CELLS ENRICHED WITH FUNCTIONAL MITOCHONDRIA | December 2020 | December 2024 | Abandon | 48 | 1 | 1 | No | No |
| 17055535 | HIGH-THROUGHPUT AUTOMATION OF ORGANOIDS FOR IDENTIFYING THERAPEUTIC STRATEGIES | November 2020 | February 2025 | Allow | 51 | 1 | 1 | Yes | No |
| 17072651 | MATRIX BOUND NANOVESICLES AND THEIR USE | October 2020 | April 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17041661 | DIFFERENTIAL KNOCKOUT OF AN ALLELE OF A HETEROZYGOUS APOLIPOPROTEIN A1 (APO1A) GENE | September 2020 | June 2025 | Allow | 57 | 1 | 1 | Yes | No |
| 16979710 | PLATFORM FOR ASSESSMENT OF THE TRANSCYTOSIS OF EXTRACELLULAR VESICLES ACROSS ENDOTHELIAL BARRIERS AND USES THEREOF | September 2020 | October 2024 | Allow | 50 | 2 | 1 | Yes | No |
| 16979482 | Culture Substrate, Method for Manufacturing Culture Substrate, and Culturing Method and Culturing Device for Stem Cell | September 2020 | January 2025 | Allow | 52 | 3 | 1 | Yes | No |
| 16971599 | EX VIVO SUBCUTANEOUS INJECTION MODEL | August 2020 | July 2024 | Allow | 47 | 1 | 1 | Yes | No |
| 16996786 | MESENCHYMAL STEM CELLS EXPRESSING CD146 RECEPTORS | August 2020 | December 2024 | Abandon | 52 | 2 | 1 | Yes | No |
| 16965762 | SCREENING METHOD FOR THE IDENTIFICATION OF CANCER THERAPEUTICS | July 2020 | October 2024 | Abandon | 51 | 1 | 1 | No | No |
| 16963414 | SAMPLE HOLDER | July 2020 | January 2025 | Allow | 54 | 2 | 0 | No | No |
| 16897885 | PROGRAMMABLE IMMUNOCYTE RECEPTOR COMPLEX SYSTEM | June 2020 | September 2023 | Abandon | 39 | 2 | 1 | Yes | No |
| 16770230 | EXTRACELLULAR VESICLES AND USES THEREOF | June 2020 | December 2024 | Abandon | 54 | 3 | 1 | No | No |
| 16761561 | Multi-Chimeric Cell and Therapy for Transplantation and Treatment of Immune Deficiencies and Genetic Disorders | May 2020 | May 2025 | Allow | 60 | 5 | 1 | Yes | Yes |
| 16760087 | CELL CHIP AND THREE-DIMENSIONAL TISSUE CHIP, AND METHOD FOR PRODUCING SAME | April 2020 | October 2024 | Allow | 53 | 2 | 2 | Yes | No |
| 16627660 | METHOD FOR SEPARATING MAMMALIAN SPERM, ARTIFICIAL INSEMINATION METHOD, AND IN VITRO FERTILIZATION METHOD | December 2019 | September 2024 | Allow | 57 | 2 | 1 | No | No |
| 16658556 | SYSTEMS AND METHODS FOR DETERMINING CELL CONTRACTILITY | October 2019 | June 2025 | Allow | 60 | 2 | 1 | Yes | No |
| 16325889 | LIFE EXTENSION AGENT | February 2019 | February 2025 | Abandon | 60 | 6 | 0 | Yes | Yes |
| 15557312 | COMPOSITION FOR TREATING ARTICULAR CARTILAGE DEFECTS | January 2018 | March 2025 | Abandon | 60 | 8 | 1 | No | No |
| 15712294 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF EPIDERMOLYSIS BULLOSA | September 2017 | November 2024 | Abandon | 60 | 9 | 1 | Yes | Yes |
| 15301587 | MICROTENTACLE IMAGING IN PATIENT TUMOR SAMPLES | October 2016 | July 2024 | Allow | 60 | 7 | 1 | Yes | Yes |
| 14972535 | Method and Composition for Hypothermic Storage of Placental Tissue | December 2015 | July 2020 | Abandon | 55 | 7 | 0 | Yes | Yes |
| 13693084 | COMPOSITIONS AND METHODS FOR TREATMENT OF VITILIGO | December 2012 | November 2014 | Allow | 23 | 3 | 0 | Yes | No |
| 13630882 | ALTERNATING ELECTRIC CURRENT DIRECTS, ENHANCES, AND ACCELERATES MESENCHYMAL STEM CELL DIFFERENTIATION INTO EITHER OSTEOBLASTS OR CHONDROCYTES BUT NOT ADIPOCYTES | September 2012 | September 2014 | Allow | 24 | 2 | 0 | Yes | No |
| 13433089 | BIOMASS SHOCK PRETREATMENT | March 2012 | February 2014 | Allow | 23 | 1 | 1 | Yes | No |
| 13356664 | Non-sterile fermentation of bioethanol | January 2012 | November 2013 | Allow | 22 | 1 | 0 | Yes | No |
| 13254287 | ENHANCING COAGULATION OR REDUCING FIBRINOLYSIS | September 2011 | November 2013 | Allow | 27 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KNIGHT, TERESA E.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KNIGHT, TERESA E works in Art Unit 1634 and has examined 56 patent applications in our dataset. With an allowance rate of 80.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 46 months.
Examiner KNIGHT, TERESA E's allowance rate of 80.4% places them in the 43% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by KNIGHT, TERESA E receive 2.14 office actions before reaching final disposition. This places the examiner in the 72% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by KNIGHT, TERESA E is 46 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +9.4% benefit to allowance rate for applications examined by KNIGHT, TERESA E. This interview benefit is in the 44% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 27.9% of applications are subsequently allowed. This success rate is in the 39% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 30.4% of cases where such amendments are filed. This entry rate is in the 36% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 59% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 127.3% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.